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Abstract
Background: Matrix metalloproteinase-28 (MMP-28) is a poorly understood member of the
matrix metalloproteinase family. Metalloproteinases are important mediators in the development
of the nervous system and can contribute to the maturation of the neural micro-environment.
Results: MMP-28 added to myelinating rat dorsal root ganglion (DRG) co-cultures reduces
myelination and two antibodies targeted to MMP-28 (pAb180 and pAb183) are capable of binding
MMP-28 and inhibiting its activity in a dose-dependent manner. Addition of 30 nM pAb180 or
pAb183 to rat DRG cultures resulted in the 2.6 and 4.8 fold enhancement of myelination
respectively while addition of MMP-28 to DRG co-cultures resulted in enhanced MAPK, ErbB2 and
ErbB3 phosphorylation. MMP-28 protein expression was increased within demyelinated lesions of
mouse experimental autoimmune encephalitis (EAE) and human multiple sclerosis lesions
compared to surrounding normal tissue.
Conclusion: MMP-28 is upregulated in conditions of demyelination in vivo, induces signaling in
vitro consistent with myelination inhibition and, neutralization of MMP-28 activity can enhance
myelination in vitro. These results suggest inhibition of MMP-28 may be beneficial under conditions
of dysmyelination.
Background
The generation of myelin during development or repair in
the peripheral and central nervous systems involves com-
plex signaling between the neuron and the surrounding
glial cells [1]. Although the correlation between axon cal-
iber and the elaboration of myelin has been established
[2-5], recent studies have started to elucidate the molecu-
lar cues that are involved in regulation of myelin forma-
tion [6-8]. Axonal Neuregulin-1 (Nrg-1) signaling
stimulates either glial proliferation [9] or induces the dif-
ferentiation of nonmyelinating Schwann cells and oli-
godendrocytes resulting in myelination depending on
localization and amount of Nrg-1 [8]. The explanation of
these opposing activities may relate to the downstream
signaling pathways activated by Nrg-1. For example, acti-
vation of PI3K downstream of Nrg-1/ErbB receptor signal-
ing is required for myelination [10,11]. Alternatively,
MAPK activation can also occur following ErbB phospho-
rylation resulting in inhibition of myelination [11]. The
details of the intracellular signaling controlling this bal-
ance between proliferation and differentiation are still
being elucidated but have been suggested to involve Nrg-
1 isoform expression, type I, II, or III [8,12] and proteoly-
sis [8,13,14]. Nrg-1 is cleaved in distinct regions by the β-
secretase BACE-1 or by metalloproteinase activity [14].
For example, Nrg-1 type III contains a membrane bound
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domain. BACE-1 cleaves C-terminal to the EGF domain of
Nrg-1 type III allowing access to ErbB 4 receptors while
MMP activity cleavage occurs N-terminal to the EGF
domain. Cleavage at both sites leads to the generation of
a soluble EGF domain [15]. Taveggia et. al. [8] have
shown that increased levels of membrane bound Nrg-1
lead to myelination while the proteolytically processed
soluble form is proliferative in the PNS (Fig 1). Recently,
a role for NRG-1 type III in the promotion of oligodendro-
cyte mediated myelination has also been shown [16].
MMP activity is known to be important for the proper
development of multiple aspects of the neural microenvi-
ronment [17]. Data from our laboratory suggests that dur-
ing development, MMP-28 expression is predominantly
neural and peaks in the mouse at embryonic day 14. In
addition, protein expression is inversely correlated with
the expression of myelin-associated glycoprotein (MAG)
during nerve regeneration [18]. Given the temporally reg-
ulated pattern of expression of MMP-28 prior to myelina-
tion in both developmental and regenerative states, it is
likely that MMP-28 plays a functional role in the matura-
tion of nerves. As MMP-28 downregulation precedes mye-
lination and MMP activity is known to regulate molecules
related to this process (Neuregulin, Bace-1, ErbB recep-
tors), it is possible that MMP-28 negatively regulates the
formation of myelin. This led us to hypothesize that inhi-
bition of MMP-28 activity will result in increased or earlier
myelination. Here we show that polyclonal antibodies
that recognize two distinct regions of MMP-28 bind
Myelination signalingFigure 1
Myelination signaling. Neuregulin signaling can lead to a myelinating, proliferative, or migratory response depending on fac-
tors such as membrane association or receptor binding. Cleavage of Neuregulin-1 (III) is mediated by Bace1 and MMP proteol-
ysis.Page 2 of 14
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lytic activity. In rat primary DRG co-cultures of neurons
and glial cells, an in vitro model of myelination, these anti-
bodies enhance the expression of axon associated MAG,
suggesting a beneficial role of inhibiting MMP-28 during
early myelination. Additionally, MMP-28 treatment
enhances MAPK phosphorylation, induces rapid phos-
phorylation of ErbB2 and ErbB3, and reduces phosphor-
ylation of PI3K in myelinating rat DRG co-cultures,
changes likely to be inhibitory to the development of
myelin. Finally, we demonstrate for the first time that
MMP-28 protein levels can be found at increased levels in
both mouse experimental autoimmune encephalitis
(EAE) spinal cord and in human cerebellar multiple scle-
rosis lesions. Together, these results suggest that MMP-28
may be a suppressor of myelination and that inhibition of
MMP-28 may be beneficial in promotion of myelin repair.
Results
MMP-28 added to DRG Co-cultures reduces development 
of myelin
Previous data from our laboratory suggested that down-
regulation of MMP-28 expression in the neuron was per-
missive for the development of myelin [18] but it is
unclear if aberrant MMP-28 expression would effect mye-
lin elaboration. To ascertain if MMP-28 directly inhibits
myelination, DRG co-cultures were established and
induced to myelinate by the addition of ascorbic acid.
Using this system, myelination of axons by Schwann cells
can be induced [19]. To verify that our cultures represent
PNS cells, S-100, Neurofilament, and Claudin-11 and O4
staining was carried out on 14 day myelinated DRG-
derived cells to identify Schwann cells, neurons, and oli-
godendrocytes respectively (Fig 2A). 64 ± 8% of all cells
were identified as Schwann cells by expression of S-100.
Less than 1% of the total cells were identified as neurons
by Neurofilament staining while O4 and Claudin-11 pos-
itive cells were not detected. It remains possible that a
small percentage of cells in these cultures are oligodendro-
cytes however based on morphology and staining, the cul-
tures represent PNS myelination. MMP-28 was included
in the media at concentrations of 0, 10 or 20 nM on day 0
and day three following the induction of myelination.
MMP-28 treatment during the early stages of myelination
resulted in a dose-dependent reduction of axon associated
myelin associated glycoprotein (MAG), a marker of mye-
lination, significantly reducing myelin at the 20 nM con-
centration (Fig 2B–C).
Polyclonal anti-MMP-28 antibodies bind MMP-28
Peptides from regions N- and C-terminal to the active site
of human MMP-28 were used to immunize rabbits for the
generation of the polyclonal anti-MMP-28 antibodies Ab
180 and pAb 183. Antisera were purified by peptide affin-
ity chromatography followed by Protein G purification.
One of the peptides was found to have the closest amino-
acid homology to MMP-10 (23%) while no homology
was found in the other peptide to any MMPs or other pro-
teins. In binding and activity assays, MMP-10 was used as
an MMP containing a related protein sequence and MMP-
2 was used as a non-related MMP. To determine antibody
specificity, 100 ng of purified human MMP-28, MMP-2,
and MMP-10 were loaded on nitrocellulose membranes
by SDSPAGE followed by Western blotting. Both antibod-
ies pAb180 and pAb183 were found to recognize the
mature form of human MMP-28 (approximately 45 kDa)
MMP-28 protein reduces myelinationFigure 2
MMP-28 protein reduces myelination. A) Identification 
of cell types present in DRG co-cultures. Green represents 
S-100 detection, red represents Neurofilament. Nuclei coun-
terstained with DAPI. B) Immunocytochemistry of 6 day 
myelinating DRG co-cultures. Arrow indicates a representa-
tive MAG + axon, arrowhead indicates a representative 
MAG – axon. Green = MMP-28, Red = MAG. Blue = DAPI. 
B) Percent of myelinated axons following 6 days of myelina-
tion in the presence of 0, 10, or 20 nM MMP-28. *p = 0.006. 
Data represent the mean of three wells ± Standard deviation.Page 3 of 14
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not recognize MMP-2 (72 kDa), or MMP-10 (58 kDa pro-
form or 48 kDa mature-form) (Fig 3). The 59 kDa pro-
form of MMP-28 in the purified protein sample was
detectable upon over exposure (data not shown). The pol-
yclonal antibodies were also found to cross react with rat
MMP-28 as determined by Western blot analysis of pro-
tein extracts of myelinating rat DRG samples. The 59 kDa
pro-form of the protein was detectable in the d14 myeli-
nating rat DRG extracts. The mature form was not detected
in these samples, however, 14 day myelinating cultures
express low levels of MMP-28 [18] compared to cultures
earlier in the myelination program and the cleaved form
may not be generated in these cells at this later time point.
Bands corresponding to the pro- and mature form of rat
MMP-28 were detected by Western blot of freshly isolated
E17 DRGs (Fig 3) suggesting that active MMP-28 is
present during the early timepoints of the development of
myelin in this DRG model of myelination.
pAb180 and pAb183 inhibit MMP-28 proteolysis
To determine if the anti-MMP28 polyclonal antibodies
inhibit MMP-28 activity, 10 nM MMP-28 was pre-incu-
bated with pAb180 or pAb183 at varying concentrations
for one hour at 37°C and then assessed for proteolytic
activity after 24 hours against an artificial fluorescent pan-
MMP substrate. Both antibodies were found to signifi-
cantly inhibit the activity of MMP-28 at 0.5:1 and 3:1
molar ratio of antibody to MMP28 (Fig 4A). pAb180
inhibited MMP-28 by 66.2%* at 5 nM and 97.6%** at 30
nM while pAb183 inhibited MMP-28 by 60.3%* at 5 nM
and 69.1%* at 30 nM (* = p ≤ 0.05, ** = p ≤ 0.01). When
measured through 5 hours, enzymatic activity of 100 nM
MMP-28 was inhibited in a dose dependent manner by
pAb180 or pAb183 while the activity of human MMP-2
(10 nM) or MMP-10 (100 nM) was not inhibited by the
addition of 60 or 100 nM pAb180 or pAb183, (Fig 4B).
No inhibition was detected in MMP-2 or MMP-10 activity
following 24 hours under any of the conditions evaluated
(data not shown). These data demonstrate that pAb180
and pAb183 are capable of specifically inhibiting the
activity of MMP-28 against a synthetic substrate in vitro.
Anti-MMP28 antibodies enhance myelin formation in vitro
Established rat DRG cultures were grown for 6 days under
myelinating conditions, an early time point in the devel-
opment of myelin in this system, at which point 30 nM
pAb180 or 30 nM pAb183 was added and the cultures
were incubated for 24 hours. MMP-28 is a secreted, mem-
brane associated protein [20], is detectable by immun-
ofluorescence at this time point in DRG co-cultures [18]
and is therefore expected to be accessible to anti-MMP-28
antibodies in this system. Assessment of myelination was
carried out using a fluorescently labeled antibody to mye-
Polyclonal anti-MMP-28 antibodies recognize MMP-28Figure 3
Polyclonal anti-MMP-28 antibodies recognize MMP-28. Western blot analysis of 1/10 fraction of total protein isolated 
from one well of d14 (+14) myelinating rat DRG co-cultures or freshly isolated E17 rat DRGs (+0) or 100 ng of purified MMP-
2, MMP-10, or MMP-28. Primary antibody incubation was performed using 50 ng/ml anti-MMP-28 pAb180 and pAb183.Page 4 of 14
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MMP-28 antibodies specifically inhibit MMP-28Figure 4
MMP-28 antibodies specifically inhibit MMP-28. A) Polyclonal antibodies to MMP-28 inhibit proteolytic activity. 10 nM 
MMP-28 was pre-incubated for 1 hour at room temperature with 5 or 30 nM anti-MMP-28 pAb180 or pAb183 and subse-
quently incubated with the Omni-MMP substrate for 24 hours. Data shown as relative fluorescent units or tabulated as % inhi-
bition compared to no antibody controls. Summary of two independent experiments ± SEM (* p ≤ 0.05, ** p ≤ 0.01). B) 100 nM 
MMP-28, 100 nM MMP-10 or, 10 nM MMP-2 was pre-incubated for one hour at room temperature with pAb180 or pAb183 or 
IgG control at the indicated concentrations and subsequently incubated with the Omni-MMP substrate. Relative fluorescence 
was measured at the indicated time points. Summary of two independent experiments ± SEM.
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ments we have found that a small percentage of axons
have associated MAG at this early time point. In all
groups, the majority of axons did not have associated
MAG; however, antibody treatment resulted in increased
MAG expression in some axon bundles (Fig 5A). In
untreated cultures, 2.8% ± 0.6% of axon bundles had
detectable axon associated MAG staining while in pAb180
or pAb183 treated cultures 7.5% ± 0.3% or 13.6% ± 1.4%
of bundles respectively were found to have axon associ-
ated MAG expression. This equates to 2.6* and 4.8* fold
increases for pAb 180 and pAb183 treated cultures respec-
tively (* = p ≤ 0.05 vs. control) (Fig 5B).
Alteration of signaling pathways after MMP-28 inhibition
To begin to understand the mechanism responsible for
increased myelination seen in DRG cultures with anti-
MMP-28 antibodies, we evaluated the ability of MMP-28
to alter signaling pathways that are known to be impor-
tant in the development of myelin.
DRG co-cultures were induced to myelinate for 14 days. At
this time point endogenous MMP-28 is reduced and a
substantial percentage of cells are undergoing myelina-
tion and would be expected to have activated myelination
related pathways. Cells were then treated with fresh mye-
lination media containing NGF with or with out 10 nM
MMP-28. Myelination media contains NGF and is
expected to activate signaling pathways including MAPK
and PI3K downstream of cognate neurotrophin (Trk or
p75) receptors [21] but is not expected to result in phos-
phorylation of ErbB receptors. The addition of fresh
media resulted in a minor increase in phosphorylated
MAPK within 10 minutes which was enhanced in the pres-
ence of MMP-28 (Fig 6A). In contrast, the phosphoryla-
tion of the p55 subunit of PI3K was inhibited in the
presence of additional MMP-28 suggesting a resultant
decrease in signaling responsible for the development of
myelin. Interestingly, both ErbB2 and ErbB3 were rapidly
phosphorylated following MMP-28 treatment while the
addition of fresh myelination media alone did not result
in activation of these receptors. The receptors ErbB2 and
ErbB3 are known to be involved in both myelination and
proliferation [6,22] however, the presence of MAPK phos-
phorylation suggests a proliferative rather than myelina-
tion related response [23]. As the DRG co-culture system
contains a mixed population of cell types, we were inter-
ested in determining if the altered signaling occurred in
cells involved in the ongoing process of myelination. To
identify the cell type with altered signaling following
MMP-28 treatment, immunofluorescence was performed
on d14 myelinating DRG co-cultures treated with 30 nM
IgG alone, or 10 nM MMP-28 with 30 nM IgG, pAb180,
or pAb183. Phospho-ErbB3 was not detected in IgG
treated control cultures or in cultures treated with MMP-
28 in the presence of pAb180 or pAb183 but was detecta-
ble along axons in cells of IgG+MMP-28 treated cultures
(Fig 6B). While it remains to be shown if the response
localized to this area is within the neurons or glial cells, it
is clear that the signaling changes do occur in the micro-
environment of myelinating cells. The loss of ErbB3 phos-
phorylation in the presence of inhibitory MMP-28
antibodies suggests that the proteolytic activity of MMP-
28 is needed for the observed changes in signaling follow-
ing treatment. These data indicate that MMP-28 alters the
signaling in myelinating DRG cultures, resulting specifi-
cally in increased phosphorylation of pathways associated
with proliferation rather than myelination in undifferen-
tiated Schwann cells, and that pAb180 and pAb183
inhibit this activity. Phosphorylation of these signaling
pathways in myelinating cells within the context of these
DRG co-cultures may not be sufficient to elicit a prolifer-
ative response, however, to address this possibility DRG
co-cultures grown under myelinating conditions for 14
days were treated with 10 nM MMP-28 and analyzed for
incorporation of a fluorescently labeled DNA binding
agent to detect any increases in DNA content (Fig 6C). No
increase in cell number as measured by DNA content was
detected 24 hours after MMP-28 treatment. Alternatively,
DRG co-cultures prior to myelination induction (2 days in
culture) were treated with 10 nM MMP-28 for 24 hours
and analyzed for the presence of the proliferation marker
proliferating cell nuclear antigen (PCNA) (Fig 6D). No
increase in proliferation was detected under these condi-
tions, suggesting that the alteration in signaling due to
MMP-28 treatment may not induce proliferation in this
system under these conditions.
Increased MMP-28 protein in demyelinating lesions
To determine if MMP-28 is expressed in demyelinating tis-
sues in vivo, MMP-28 expression in two states of demyeli-
nation was analyzed. First, demyelination in mice was
induced using experimental autoimmune encephalitis
(EAE) by immunizing mice with a peptide fragment of
myelin oligodendrocyte glycoprotein (MOG). This model
of demyelination is a commonly used model for the
human demyelinating disease multiple sclerosis
(MS)[24]. Expression of MMP-28 and MAG in spinal cord
sections from mice with clinical scores of greater than 2
(unilateral hind limb paralysis) showed that MMP-28 was
expressed within lesions of reduced MAG expression and
at least in part found along axons (Fig 7A). In contrast,
MMP-28 expression was found at a lower level in adjacent
tissue with continuous MAG staining. This pattern of
MMP-28 expression was consistent in the three EAE sam-
ples analyzed while MMP-28 was not detected in spinal
cord sections from normal, age matched spinal cord sec-
tions (data not shown). Second, increased MMP-28
expression appears to occur in brain tissue of human MS
patients. Lesions with reduced myelination were identi-Page 6 of 14
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pAb 180 and pAB 183 increase axon associated MAGFigure 5
pAb 180 and pAB 183 increase axon associated MAG. A) MAG immunofluorescence of myelinating rat DRG co-cul-
tures. Merged or MAG only image of axon bundles of similar size with or without pAb183. Image shows examples of axon bun-
dles determined to be MAG negative (No Ab control) or MAG positive (+30 nM pAb183). Red staining is MAG, Green is 
MMP-28, Nuclei are stained blue with DAPI. B) Quantification of MAG positive axon bundles following anti-MMP-28 treatment. 
Data represent mean of 3 independent experiments ± SEM.
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Signal pathway changes in MMP-28 treated DRG culturesFigure 6
Signal pathway changes in MMP-28 treated DRG cultures. A) Western blot analysis of pErbB-2, pErbB3, pPI3K (p55/
p85) and phosphoMAPK in rat DRG co-cultures at 0, 1, 5, 10, 15, and 20 minutes following addition of fresh media with or 
without 10 nM MMP-28. Equal protein loading was determined by Ponceau-S staining of the membrane (not shown) and 
Coomassie staining of a parallel, equally loaded gel. B) Immunofluorescence of pErbB3 in DRG co-cultures 20 minutes after 
addition of fresh media containing 10 nM MMP-28 preincubated with 30 nM rabbit IgG, pAb180 or pAb183. Blue:DAPI, 
Red:pErbB3, Green:Acetylated C,D) Determination of proliferation in DRG co-cultures following MMP-28 treatment using 
PCNA. C) Relative fluorescence units were counted in 14 day myelinating cultures in control and treated samples. D) Percent 
of proliferating cells after 2 days in culture was determined by counting PCNA positive nuclei. N = 3, ± SD.
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MMP-28 expression in EAE and MS tissueFigure 7
MMP-28 expression in EAE and MS tissue. A) Immunofluorescence of mouse EAE spinal cord. Panels represent (from left 
to right) region with reduced MAG expression (lesion), normal adjacent tissue (NAT) and a separate lesioned area at higher 
magnification. B) Luxol fast blue and immunofluorescent staining of human cerebellar MS tissue. a: Luxol fast blue staining iden-
tifying a lesion containing rarefied myelination. b: Merged MAG (Red), MMP-28 (Green), and DAPI (Blue) staining of MS lesion, 
c: normal myelinated region (from b), d: region within the lesion demonstrating increased MMP-28 expression (from b). C) 
Western blot analysis of proteins obtained from cortices of multiple sclerosis patients or normal brains. Four independent nor-
mal samples and four independent MS samples are shown.
BMC Neuroscience 2008, 9:83 http://www.biomedcentral.com/1471-2202/9/83fied in cerebellar tissue from a patient with multiple scle-
rosis by Luxol blue staining (Fig 7B). These regions are in
areas of the cerebellum expected to be myelinated and
surrounded by normal, myelinated tissue evidenced with
more intense Luxol blue staining. MAG staining of serial
sections also demonstrated loss of myelin. As expected, in
regions identified as normal by Luxol blue staining, MAG
protein is strongly expressed indicating normal myelina-
tion whereas in the identified lesion, MAG was greatly
reduced. Within the boundaries of the identified MS
lesions, MMP-28 was detected along individual axons
while no such staining was found throughout the normal
myelinated regions of the cerebellum. MAG staining was
not found to co-localize to these structures. As in the nor-
mal mouse spinal cord tissue, no axon associated MMP-
28 was detected in normal human cerebellar tissue (data
not shown). Additionally, MMP-28, as detected by West-
ern blot in multiple samples, is elevated in cortex taken
from MS patients compared to cortex tissue from normal
brains (Fig 7C). In the normal samples, only the mature
(45 kDa) form of the protein was detected while in the MS
samples, increased levels of both the pro- (59 kDa) and
the mature form of the protein were detected in some, but
not all of the diseased tissues. Further characterization of
MMP-28 protein expression in diseased human samples
will help to clarify the extent of MMP-28 involvement in
multiple sclerosis, however, these results demonstrate that
in mouse EAE and human MS tissues, an increase in axon
associated MMP-28 can be detected.
Discussion
We have shown previously that MMP-28 is expressed in
the developing nervous system in a temporally regulated
manner [18]. This expression is inversely correlated with
the expression of MAG in two models of Xenopus laevis
nerve regeneration and in myelinating rat DRG cultures.
These data suggested the possibility that MMP-28 may
play a role in the development of myelin during normal
development and in neural regeneration. Here we show
that exogenously added MMP-28 reduces myelination,
that activity in vitro can be inhibited by antibodies to
MMP-28, and that such inhibition results in enhanced
formation of myelin. Specific inhibitors of MMP-28 are
not known; therefore, we generated antibodies to two dis-
tinct regions of MMP-28 with the goal of developing
inhibitory antibodies. The peptides used were unique to
MMP-28 and not expected to cross react with other MMPs.
In addition, the locations of the epitopes were expected to
be near the active site based on the known sequence of
MMP-28. Both antibodies were shown to bind and inhibit
MMP-28 activity but did not bind or inhibit MMP-2 or
MMP-10. MMP-28 is expressed by DRG neurons within
the first 14 days after initiation of myelination by ascorbic
acid [18]. As MMP-28 expression is downregulated during
the period of myelination in vitro as well as in vivo during
nerve regeneration, it is possible that MMP-28 activity is
antagonistic to myelination. If so, blocking its proteolytic
activity may result in enhancement of the myelination
program. Addition of either of the two neutralizing anti-
MMP-28 antibodies (pAb 180 or pAb 183) to myelinating
DRG cultures resulted in an increase in axon associated
MAG staining. This strengthens the hypothesis that neuro-
nal MMP-28 expression after the onset of myelination acts
as an inhibitor of the development of myelin. It is not
known if MMP-28 acts on the matrix of the neural micro-
environment or cleaves cell surface molecules involved in
signaling. Illman et al. [20] have shown that MMP-28 is
membrane localized, can induce an epithelial-to-mesen-
chymal transition in lung adenocarcinoma cells and alters
signaling mediated through TGF beta. We were therefore
interested in the signaling changes that may be mediated
by MMP-28 in our cell culture system and chose to evalu-
ate changes in the ErbB activated pathways as signaling
downstream of ErbB receptors regulates myelination. Our
initial observations suggest that addition of MMP-28
results in rapid phosphorylation of ErbB2 and ErbB3 and
enhanced MAPK phosphorylation. Activation of ErbB2
and ErbB3 on glial cells can result in proliferative signals
or myelinating signals [22,23] and does not on its own
suggest which pathway might be affected. However, ErbB
receptor activity in myelinating glial cells is characterized
by reduced phosphorylation of MAPK and enhanced PI3K
phosphorylation. The enhanced MAPK phosphorylation
following MMP-28 treatment in DRG co-cultures coupled
with decreased activation of the p55 subunit of PI3K, the
active signaling pathway during myelination, are consist-
ent with MMP-28 activity enhancing the non-myelination
pathway downstream of the ErbB receptors. It is not yet
clear if MMP-28 activity is directly involved in the genera-
tion of these intracellular phosphorylation events but
there is evidence for MMP-mediated signaling within the
nervous system. Of particular interest, both Neuregulin-1
and the ErbB receptors are known to be processed by
MMP proteolysis [9,13,25]. As MMP processing of NRG-1
leads to soluble NRG and the myelinating signal is
dependent on juxtacrine signaling, it is possible that
MMP-28 cleaves NRG-1 in this system and that inhibiting
MMP-28 activity results in accumulation of membrane
bound NRG-1. In previous studies, we identified
increased proteolysis of NCAM and Nogo-A following
MMP-28 treated of embryonic rat brains [18]. Alterations
in NCAM expression may be involved in the development
of myelin [26,27] and Nogo-A, a component of myelin,
regulates multiple aspects of glial and neural cell biology
[28]. Cleavage of either protein could potentially result in
soluble biologically active fragments or loss of function
through degradation. Alternatively, the degradation of
MAG by MMP-28 is a possibility. Previously, we showed
that in vitro, at much higher doses than used in these
experiments, MAG may be a substrate for MMP-28 [18]Page 10 of 14
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in the tissues as it develops until the down regulation of
MMP-28. The inverse expression of MMP-28 and MAG
suggests that MMP-28 regulation is at least temporally
coordinated with the myelination program even if it
relates only to the post-transcriptional control of MAG.
However, the correlation of MAG staining within myeli-
nated and demyelinated regions of both mouse and
human nervous tissue with Luxol Blue staining, which
stains the lipid component of myelin, suggests that MAG
can be used as marker of myelination even in the presence
of varying levels of MMP-28. When taken together with
data suggesting that signaling related to the myelination
program is altered when exogenous MMP-28 is added,
these data support the use of MAG reduction to represent
a delay or inhibition of myelination. Further work will be
required to determine the essential target of MMP-28
action in vivo.
While the experiments performed in vitro demonstrate a
role for MMP-28 in regulating PNS myelination, we were
curious if a similar role might be involved in the develop-
ment or maintenance of CNS myelin. We report in this
study for the first time that increased MMP-28 expression
can be detected within demyelinated lesions of mouse
EAE and human MS nervous system tissue. The increase in
MMP-28 detected in both cases lends further support to
the hypothesis that MMP-28 activity is involved in the reg-
ulation of myelin. It can not be determined from these
experiments if MMP-28 activity in these tissues is respon-
sible for the demyelination or if it expressed prior to or
during any remyelination, however, the timing of the EAE
progression in the tissue (21 days after induction) and the
increased nuclei (presumably infiltrating immune cells)
in both tissues, suggest that these lesions may be actively
demyelinating rather than undergoing the process of
remyelination. While these experiments represent a small
sample size and need to be followed up to determine the
specific lesion types that demonstrate this altered expres-
sion, the results suggest that MMP-28 may be a relevant
target for therapeutic intervention in MS. It is important to
note that while there is consistency in MMP-28 expression
during development in the CNS and PNS, and between
dysmyelination states (PNS renervation, mouse EAE, and
MS) the functional implications of altered MMP-28
expression in the CNS may not be the same as in the PNS.
Also remaining to be characterized is the role of activation
of MMP-28. MMP function is carefully controlled by
cleavage of the pro- form to generate the active form of the
protein. The sequence of proMMP-28 contains a putative
furin recognition sequence but the details of activation for
this enzyme in vivo are unknown.
Validation of the functional role of MMP-28 in the CNS
remains to be carried out. Although the specific mecha-
nism is unknown, MMP-28 appears to play a role in the
development of myelin. We suggest that in the nervous
system, signaling pathways such as activation of the ErbB-
MAPK cascade can be altered in response to MMP-28-
induced proteolysis and that continued expression of this
protease results in inhibition of robust myelination. If
MMP-28 activity plays a similar role in modulating myeli-
nation in vivo, inhibition of this protease may represent a
therapeutic mechanism for enhancing remyelination in
demyelinating diseases.
Conclusion
Although the specific mechanism is unknown, MMP-28
appears to play a role in the development of myelin. We
suggest that in the nervous system, signaling pathways
such as activation of the ErbB-MAPK cascade can be
altered in response to MMP-28-induced proteolysis and
that continued expression of this protease results in inhi-
bition of robust myelination. If MMP-28 activity plays a
similar role in modulating myelination in vivo, inhibition
of this protease may represent a therapeutic mechanism
for enhancing remyelination in demyelinating diseases.
Methods
Generation of polyclonal antibodies
Rabbit polyclonal antibodies were generated to two dis-
tinct peptides of human MMP-28 from regions N-termi-
nal or C-terminal to the active site. These epitopes were
chosen as they are near the active site of MMP-28 and
expected to be accessible to antibodies based on computer
modeled predictions of MMP-28 structure. In addition,
they are unique to MMP-28 and not expected to bind to
other MMPs. Antibodies were affinity-purified from antis-
era using the corresponding antigen peptides. Antisera
were subsequently further purified using protein G spin
columns (GE Healthcare) according to the manufacturer's
protocol. These purified antibodies, pAb180 and pAb183,
were quantified by absorbance at 260 nM and character-
ized for their ability to bind and modify activity of MMP-
28 protein.
Antibody binding
100 ng of purified recombinant human MMP-28, MMP-2,
and MMP-10 were loaded onto a 4–12% bis-tris gel and
electrophoresed at 125 V for 90 minutes under non-reduc-
ing conditions. For detection of rat MMP-28, 14 day mye-
linating rat DRG co-cultures grown in 24 well plates were
lysed directly in the well with 200 ul of lysis buffer (50
mM, 1 mM EDTA, mM PMSF, 300 mM NaCl, 1 mg/ml
BSA, 2% NP-40, with sodium orthovanadate, hydrogen
peroxide, and Complete protease inhibitors (Roche)
added just before use to final concentrations of 10 μM,
0.01%, and 1× respectively). LDS sample buffer (Invitro-
gen) was added to a final 1× concentration. One tenth of
the total protein prepared from one well was analyzed byPage 11 of 14
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lose membrane at 30 volts for 90 minutes. The mem-
branes with recombinant MMPs or rat protein extract were
blocked overnight in 5% non-fat dry milk/TBST at 4°C
followed by incubation in 0.5% NFDM/TBST with either
pAb180 or pAb183 at 50 ng/ml. Blots were washed 3
times in TBST and incubated in 0.5% NFDM/TBST with
an anti-rabbit HRP-conjugated secondary antibody (10
ng/ml) for 1 hour. The blots were then washed 6 times for
ten minutes in what in TBST. Chemiluminescent detec-
tion was carried out using SuperSignal West-Femto
(Pierce, Rockford, IL). Radiographic film was exposed to
the blots to detect the presence of MMP-28.
MMP-28 activity
MMP-28 protein activity was measured using a fluores-
cently labeled substrate. The fluorescently labeled and
quenched peptide, Omni-MMP (Biomol, Plymouth Meet-
ing, PA), a pan-MMP substrate, was dissolved in DMSO to
a concentration of 20 mM. MMP protein was diluted in
PBS. MMP-28, 10× protease assay buffer (500 mM HEPES
pH 7.0, 100 mM CaCl2, 0.5% Brij-35, 100 μM ZnCl2) and
substrate were added to a final concentration of 1× assay
buffer, 10 μM substrate in 100 μl final volume. Reactions
were carried out in black 96 well plates covered with alu-
minum foil at 37°C. Fluorescence was measured using a
Victor3 plate reader (340 nM excitation, 405 nM emis-
sion) for 1 second/well.
DRG cultures
DRG cultures were established as described by Svenning-
sen et. al. (2003). Embryos were isolated at day 17 of ges-
tation from pregnant Long-Evans rats (Harlan) and DRGs
removed. Cells were washed in L15 + 10% FBS 3 times
and resuspended in Neuralbasal media (Invitrogen) with
100 ng/ml NGF (BD) and 2% B27 supplement (Invitro-
gen). Cells were grown on plates coated with Matrigel
(1:20 L15) for 4 days after plating at which point fresh
media was added with 50 μg/ml ascorbic acid (myelina-
tion media) to initiate myelination. Identification of cell
type was carried out by immunofluorescent detection of
antibodies to S-100 (Dako), Neurofilament (Chemicon),
O4 (Millipore), and Claudin-11 (Santa Cruz). Percentage
of Schwann cells or neurons was determined by counting
nuclei and S-100 or Neurofilament positive cells from
three random fields. A minimum of 149 cells were
counted per field. Determination of myelination was car-
ried out by immunofluorescent detection of MAG
(Chemicon), a marker for the early stages of myelination.
Experiments were performed in early myelinating cultures
(14 days or less under myelination permissive condi-
tions). To determine the extent of early myelination, cul-
tures were stained by immunocytochemistry for MMP-28
(Cederlane), present in axons (Werner et. al. 2007) to
detect axon bundles, DAPI to detect associated Schwann
cell nuclei and MAG to detect myelin formation as
described previously (Werner et. al. 2007) using fluores-
cently labeled secondary antibodies. Images were cap-
tured of MMP-28, DAPI, and MAG staining from three
random fields in each well. Identified axon bundles were
determined to be MAG positive or MAG negative. Scoring
was performed blinded to treatment group. A minimum
of 100 axon bundles per well were counted and myelina-
tion represented as MAG positive axon bundles compared
to total axon bundle number. Three wells per group were
counted. MMP-28 protein was expressed and purified as
described previously (Werner et al., 2007) and diluted
into myelination media. For the 0 nM MMP-28 treatment,
a volume of MMP-28 negative elution fraction equal to
the volume used for the 20 nM MMP-28 sample was
added to the myelination media.
Activation of signaling cascades in DRG co-cultures
DRG co-cultures grown in 24 well plates were induced to
myelinate for 14 days and then treated with fresh media
containing NGF with or without 10 nM MMP-28 (450 ng/
ml, 0.5 ml/well). MMP-28 added in the presence of IgG or
pAb 180 and pAb 183 was pre-incubated at room temper-
ature for 1 hour prior to addition to cultures. Antibodies
added alone to cultures for analysis of myelination were
diluted directly in myelination media. Media was aspi-
rated at 0, 1, 5, 10, 15, and 20 minutes after treatment,
cells were lysed directly in the wells and subjected to one
freeze/thaw cycle at -80°C to disassociate Matrigel. LDS
sample buffer (Invitrogen) was added to a final 1× con-
centration and samples analyzed by Western blot as
described earlier. Antibodies were obtained from Cell Sig-
naling Technologies, catalogue numbers as follows:
pErbB2 2249S, pErbB3 4784P, pMAPK 4377S, pPI3K
4228P, or LabVision: PCNA Ab-1, PC10. Equal protein
loading was confirmed by Coomassie staining of protein
in the gel after transfer and Ponceau-S staining of the
membrane prior to blocking. For immunoflourescence of
phosphoErbB3, cultures were fixed in methanol for 10
minutes followed by three washes in 0.1%Tween 20-PBS
(PBST). Nonspecific binding sites were blocked with
PBST/5% non-fat dry milk at 37°C for 1 hour followed by
incubation with primary antibody (pErbB3, Cell Signal-
ing Technologies No.4784P, acetylated tubulin, Sigma,
No. T7451) for 90 minutes at 37°C. Secondary antibodies
used were AlexaFluor-488 goat antimouse and Alexa
Fluora-555 goat anti-rabbit (Invitrogen). Nuclei are coun-
terstained with DAPI (4',6-diamidino-2-phenylindole,
Sigma). To evaluate proliferation in DRG co-cultures,
changes in DNA content was measured using the
CyQuant NF Cell Proliferation Assay kit (Invitrogen)
according to the manufacturers protocol. Briefly, equal
number of DRG cells were plated in wells of a 48 well
plate and grown under myelination permissive conditions
for 14 days at which time, 10 nM MMP-28 or an equal vol-Page 12 of 14
(page number not for citation purposes)
BMC Neuroscience 2008, 9:83 http://www.biomedcentral.com/1471-2202/9/83ume of MMP-28 negative column eluate (n = 3 wells per
group) was added to the media. After 24 hours, media was
removed and 100 μl of 1× dye binding solution was added
to the wells and incubated for 60 minutes. Fluorescence
was measured on a fluorescent microplate reader (excita-
tion at 485 nm and emission at 535 nm). Proliferation in
DRG co-cultures prior to the development of myelin was
measured by detection of PCNA by immunofluorescence
as described above. Cells were plated at equal number and
grown for 2 days at which time 10 MMP-28 or an equal
volume of MMP-28 negative column eluate was added for
24 hours. Increases in Schwann cell proliferation have
been detected after 24 hours (Lee et al., 1999). Images of
three random fields within each well were captured (min-
imum of 100 cells per field) and total cell number (DAPI
stained nuclei) and PCNA positive nuclei were deter-
mined.
Determination of myelination in tissues
EAE was established in 6–8 week old C57BL6 mice by
immunization to MOG as follows. MOG35-55(Peptide
International, Cat. PMG-3660-PI) and heat inactivated M.
Tuberculosis (H37 RA, Difco Laboratories, Cat. 231141)
were diluted to a final concentration of 1.5 mg/ml and 2.5
mg/ml respectively in CFA (Complete Freund Adjuvant,
Difco Laboratories, Cat. 231131) and emulsified by soni-
cation on ice. Mice were immunized in the right flank by
subcutaneous injection of 200 μl of MOG emulsion at day
0 and day 7 followed at t = 0 and t = 48 hours with 200 μl
of 2.5 μg/ml Pertussis toxin (List Biological Laboratories,
Cat. 181) in PBS. Development of EAE clinical signs was
monitored daily according to the following scale: 0 = No
clinical EAE symptoms, 0.5 = Distal limp or spastic tail, 1
= Limp tail, 1.5 = Limp tail and hind limb weakness, 2 =
Unilateral partial hind limb paralysis, 2.5 = Bilateral par-
tial-hind-limb paralysis, 3.0 = Complete bilateral hind-
limb paralysis, 3.5 = Complete hind-limb and unilateral
partial-forelimb paralysis, 4.0 = Total paralysis of fore and
hind-limbs, 5.0 = Moribund or death. After 21 days, the
clinical signs score for treated animals was determined to
be at 2 or higher. Immunofluorescence staining was per-
formed on 2 sections from spinal cords of three mice with
a score of 2 or greater and three normal control spinal
cords. For determination of myelination in human MS,
frozen 5 μm cerebellar tissue sections from a human MS
patient were obtained (Biomax, Ijamsville, MD). Myelina-
tion was detected by Luxol fast blue staining or MAG
immunohistochemistry. Paraffin sections were deparaffi-
nized through two changes of xylenes followed by a
graded series of methanol and a final wash in PBS while
frozen sections were thawed to room temperature before
processing. Sections were placed in 0.1% Luxol fast blue
solution (0.1 g Luxol fast blue (Acros), 0.5 ml acetic acid,
in 95% ethanol to 100 ml) for 16 hours at 56°C. The
slides are then removed from Luxol fast blue, washed in
95% ethanol, rinsed in distilled, deionized water
(ddH2O) and differentiated in 0.05% lithium carbonate
(Acros) for 30 seconds. Following differentiation, slides
were then rinsed in ddH2O and examined microscopi-
cally to verify differentiation of white matter. The slides
were then incubated in 0.1% Cresyl echt violet (American
Master Tech Scientific) for 40 seconds to counterstain
nuclei and gray matter. Excess Cresyl echt violet was
rinsed off the slides with ddH2O. The slides were differen-
tiated in 95% ethanol for 5 minutes followed by sequen-
tial dehydration in 100% ethanol and Xylenes. The
sections were permanently mounted under coverslips
using Permount (Sigma). The tissue was analyzed by light
microscopy using an upright microscope. To identify
changes in protein expression within MS and EAE lesions,
immunohistochemistry was performed using standard
techniques with antibodies to MMP-28 (Cedarlane) and
MAG (Chemicon). Nuclei were counterstained with
DAPI. For Western blot analysis of MMP-28 levels in nor-
mal or multiple sclerosis patients, frozen brain tissue sam-
ples from multiple sclerosis patients were obtained from
the Rocky Mountain Multiple Sclerosis Center and normal
brain samples were obtained from in house tissue banks
(Eli Lilly). Approximately 5 mg of tissue was cut from the
frozen samples and lysed in 500 μl 1× LDS buffer (Invit-
rogen) containing 1× reducing agent (Invitrogen). 5 μl of
each sample was loaded onto a 4–12% Bis-Tris gel and
electrophoresed under 100 V for 1 hour. The gel was
removed and stained with SimplyBlue (Invitrogen) to ver-
ify approximately equivalent protein concentrations. Elec-
trophoresis was repeated and proteins were transferred to
nitrocellulose. Western blot detection of MMP-28 was car-
ried out as described above using anti-MMP-28 (Cedar-
lane). Blots were stripped using Restore western blot
stripping buffer (Pierce) according to manufacturers
instructions and detection of acetylated tubulin (Sigma)
was carried out for normalization of protein levels. All
animal use protocols were approved by the Eli Lilly Ani-
mal Care and Use Committee.
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